Vericel Corp (VCEL) Stock
5 of the hedge funds AlphaScala tracks reported VCEL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $20.12M. Company insiders reported 0 open-market buys and 9 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
Which hedge funds own VCEL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 452K | $20.12M | +53% |
| Point72 Steve Cohen | 443K | $19.72M | +170% |
| Marshall Wace | 79K | $3.51M | -62% |
| Citadel Ken Griffin | 9K | $392.8K | -92% |
| Blackstone | 8K | $343.3K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Vericel Corp insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 6, 26 | Mara Joseph Anthony Jr | Chief Financial Officer | SELL | 14.1K | $751K |
| Nov 6, 26 | Mara Joseph Anthony Jr | Chief Financial Officer | SELL | 14.6K | $779K |
| Nov 5, 26 | Zerbe Robert L Md | Director | SELL | 500 | $28K |
| Nov 5, 26 | Zerbe Robert L Md | Director | SELL | 2.5K | $129K |
| Nov 5, 26 | Siegal Jonathan | Principal Accounting Officer | SELL | 1.5K | $79K |
| Nov 5, 26 | Flynn Sean C. | Chief Legal Officer | SELL | 15.0K | $779K |
| Nov 5, 26 | Mara Joseph Anthony Jr | Chief Financial Officer | SELL | 10.9K | $584K |
| Nov 5, 26 | Mara Joseph Anthony Jr | Chief Financial Officer | SELL | 10.4K | $560K |
| Nov 4, 26 | Zerbe Robert L Md | Director | SELL | 2.5K | $114K |
| Aug 12, 26 | Mclaughlin Kevin F | Director | SELL | 7.0K | $312K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →VCEL price chart
Powered by TradingViewWhat does Vericel Corp do?
Vericel Corporation is a biopharmaceutical company focused on the development and commercialization of innovative cellular therapies for patients with severe diseases and conditions. The company's primary purpose is to provide next-generation solutions that harness the power of a patient's own cells to repair damaged tissues and restore function. Vericel specializes in treatments for sports medicine and severe burn care, with key products including MACI, a personalized autologous cellularized scaffold for knee cartilage repair, and Epicel, a permanent skin replacement for patients with extensive burn injuries. Vericel's products serve critical roles in the biotechnology and healthcare sectors, impacting clinical outcomes for patients experiencing serious musculoskeletal and skin injuries. With headquarters in Cambridge, Massachusetts, Vericel operates at the intersection of medical innovation and patient-focused care, contributing to advancements in cellular therapy technologies. Through collaborations with medical professionals and institutions, Vericel plays a significant role in enhancing the quality of life for individuals undergoing complex surgical procedures, leading the advancement of regenerative medicine by refining techniques to produce effective treatments with the potential to transform standard practices in patient care.